Breast cancer leading cause of female claims

Aviva claims data

Cameron Roberts
clock • 2 min read

Provider, Aviva, has revealed that breast cancer is still the leading cause for claim amongst its female critical illness customers.

Of the women who claimed on an individual critical illness product, 55% were due to breast cancer. Of all cancer claims through the provider, 61% were women claiming due to breast cancer. These figures mean that breast cancer is the leading cause for women's claims across Aviva's private medical insurance and individual critical illness policies, according to the provider. Aviva also commented on how awareness of the symptoms of breast cancer had changed. In its research 75% of women knew common signs of breast cancer such as a lump or swelling in the armpit, 76% knew to look for a lu...

To continue reading this article...

Join COVER for free

  • Unlimited access to real-time news, key trend analysis and industry insights.
  • Stay on top of the latest developments around health and wellbeing, diversity and inclusion and the cost of living crisis.
  • Receive breaking news stories straight to your inbox in the daily newsletter.
  • Members only access to monthly programme 'The COVER Review'
  • Be the first to hear about our CPD accredited events and awards programmes.

Join now

 

Already a Cover member?

Login

More on Insurer

The Exeter appoints Suzy Esson as COO

The Exeter appoints Suzy Esson as COO

Effective 1 April, 2025

Cameron Roberts
clock 02 April 2025 • 1 min read
Guardian names Carlton Hood as CEO

Guardian names Carlton Hood as CEO

Joins from Responsible Life

Jaskeet Briah
clock 02 April 2025 • 2 min read
Partner Insight: How the Experience Economy is reshaping the life insurance landscape

Partner Insight: How the Experience Economy is reshaping the life insurance landscape

Generational Diversity: Different Expectations, Different Approaches

Stuart Hayman, Senior Business Consultant - Life & Pensions Insurance Practice (EMEA & APAC), Sapiens
clock 02 April 2025 • 5 min read